Sensorium Therapeutics Inc. has identified alkylated derivatives of mesembrine or mesembrenone acting as serotonin transporter (SERT) and/or phosphodiesterase PDE4 inhibitors reported to be useful for the treatment of anxiety, depression and stress disorders.
Palisade Bio Inc. has completed its analysis evaluating ex vivo bioactivation of PALI-2108, an orally administered, locally acting colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug in development for ulcerative colitis.
Humanwell Healthcare (Group) Co. Ltd. has disclosed compounds acting as phosphodiesterase PDE4 inhibitors, particularly PDE4B, reported to be useful for the treatment of respiratory, gastrointestinal, inflammatory, dermatological, ophthalmic and neurological disorders, transplant rejection and cancer.
Researchers from National Cheng Kung University and affiliated organizations have presented the discovery and preclinical evaluation of novel pyrazole derivatives that inhibit the neutrophil signaling pathway, to be developed for the treatment of inflammation.
Sichuan Haisco Pharmaceutical Co. Ltd. has identified phosphodiesterase PDE3 and phosphodiesterase PDE4 inhibitors reported to be useful for the treatment of chronic obstructive pulmonary disease (COPD) and asthma.
Ocean University of China has identified novel benzotropone derivatives acting as phosphodiesterase 4 (PDE4) and/or cAMP and cAMP-inhibited cGMP 3ʹ,5ʹ-cyclic phosphodiesterase 10A (PDE10A) inhibitors reported to be useful for the treatment of allergy, inflammatory, neurological and cardiovascular diseases.
Suzhou Suncadia Biopharmaceuticals Co. Ltd. and Jiangsu Hengrui Medicine Co. Ltd. have synthesized isoquinolone compounds acting as phosphodiesterase PDE3A and/or PDE4 inhibitors reported to be useful for the treatment of asthma, chronic obstructive pulmonary disease (COPD), sepsis, nephritis, diabetes, allergic rhinitis, allergic conjunctivitis and rheumatic diseases.
